KR970032856A - 신경보호제 - Google Patents

신경보호제 Download PDF

Info

Publication number
KR970032856A
KR970032856A KR1019960062011A KR19960062011A KR970032856A KR 970032856 A KR970032856 A KR 970032856A KR 1019960062011 A KR1019960062011 A KR 1019960062011A KR 19960062011 A KR19960062011 A KR 19960062011A KR 970032856 A KR970032856 A KR 970032856A
Authority
KR
South Korea
Prior art keywords
rapamycin
compound
administering
nmda
combination
Prior art date
Application number
KR1019960062011A
Other languages
English (en)
Inventor
장-밥티스테 갈레이
로랑 마로
까뜨린느 꼬쓰
레네 슈미트
마르쎌 레니에
히토시 나가오카
카바자 크라우디오
스티븐 쉬-순 린
캐더린 루 몰나-킴버
Original Assignee
히토시 나가오카
원본미기재
로레알
알도 파시
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
버그 이곤 이
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히토시 나가오카, 원본미기재, 로레알, 알도 파시, 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이., 버그 이곤 이, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 히토시 나가오카
Publication of KR970032856A publication Critical patent/KR970032856A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 신경보호제로서 라파마이신, 페닐트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 4-[[4-(디메틸아미노)페닐]아조]벤젠설폰산과의 라파마이신 42-에스테르, 메틸트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 또는 라파마이신-O-벤질-27-옥심을 사용하는 방법을 제공한다.

Description

신경보호제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 라파마이신, 페닐트리아졸린디온과의 라파마이시, 1,3-디엘스 알더(1,3-Diels Alder) 부가물, 4-[[4-(디메틸아미노)페닐]아조]벤젠설폰산과의 라파마이신 42-에스테르, 메틸트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 및 라파마이신-O-벤질-27-옥심으로 이루어진 그룹중에서 선택된 화합물의 유효량을 이를 필요로 하는 포유동물에게 경구, 비경구, 혈관내, 비강내, 기관지내, 경피, 또는 직장투여하는 것을 포함하여, 상기 포유동물의 신경 세포 사멸을 억제하는 방법.
  2. 제1항에 있어서, 화합물이 라파마이신인 방법.
  3. 라파마이신, 페닐트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 4-[[4-(디메틸아미노)페닐]아조]벤젠설폰산과의 라파마이신 42-에스테르, 메틸트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 및 라파마이신-O-벤질-27-옥심으로 이루어진 그룹중에서 선택된 화합물의 유효량을 이를 필요로 하는 포유동물에게 경구, 비경구, 혈관내, 비강내, 기관지내, 경피, 또는 직장 투여하는 것을 포함하여, 상기 포유동물의 발작, 머리 손상 및 신경퇴화성 질환을 치료하는 방법.
  4. 제3항에 있어서, 화합물이 라파마이신인 방법.
  5. 제3항에 있어서, 신경퇴화성 질환이 알츠하이머 질환, 근위축성 외축 경화(ALS), 에피렙시, 헌팅톤 질환 (Huntington`s Diesease), 및 파키슨 질환으로 구성되는 그룹중에서 선택되는 방법.
  6. 제5항에 있어서, 화합물이 라파마이신인 방법.
  7. 라파마이신, 페닐트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 4-[[4-(디메틸아미노)페닐]아조]벤젠설폰산과의 라파마이신 42-에스테르, 메틸트리아졸린디온과의 라파마이신 1,3-디엘스 알더 부가물, 및 라파마이신-O-벤질-27-옥심으로 이루어진 그룹중에서 선택된 화합물의 유효량을 이를 필요로 하는 포유동물에게 경구, 비경구, 혈관내, 비강내, 기관지내, 경피, 또는 직장 투여하는 것을 포함하는, 상기 화합물을 신경보호제로서 사용하는 방법.
  8. 제7항에 있어서, 화합물이 라파마이신인 방법.
  9. 제1항에 있어서, 상기 화합물을 N-메틸-D-아스파르테이트(NMDA) 또는 AMPA 길항제와 배합하여 투여하는 것을 추가로 포함하는 방법.
  10. 제1항에 있어서, 상기 화합물을 NMDA와 AMPA길항제 모두와 배합하여 투여하는 것을 추가로 포함하는 방법.
  11. 제3항에 있어서, 상기 화합물을 NMDA와 AMPA길항제와 배합하여 투여하는 것을 추가로 포함하는 방법.
  12. 제3항에 있어서, 상기 화합물을 NMDA 또는 AMPA길항제 모두와 배합하여 투여하는 것을 추가로 포함하는 방법.
  13. 제7항에 있어서, 상기 화합물을 NMDA 또는 AMPA길항제와 배합하여 투여하는 것을 추가로 포함하는 방법.
  14. 제7항에 있어서, 상기 화합물을 NMDA와 AMPA길항제 모두와 배합하여 투여하는 것을 추가로 포함하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960062011A 1995-12-07 1996-12-05 신경보호제 KR970032856A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07
US60/008,337 1995-12-07
ITRM95A000824 1995-12-15
FR95-15335 1995-12-22
JP7-337558 1995-12-25
JP7-337557 1995-12-25

Publications (1)

Publication Number Publication Date
KR970032856A true KR970032856A (ko) 1997-07-22

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960062011A KR970032856A (ko) 1995-12-07 1996-12-05 신경보호제

Country Status (23)

Country Link
EP (1) EP0778023B1 (ko)
JP (1) JPH09183727A (ko)
KR (1) KR970032856A (ko)
CN (1) CN1112925C (ko)
AR (1) AR008747A1 (ko)
AT (1) ATE234095T1 (ko)
AU (1) AU700653B2 (ko)
BR (1) BR9605895A (ko)
CA (1) CA2192298A1 (ko)
CZ (2) CZ354496A3 (ko)
DE (1) DE69626610T2 (ko)
DK (1) DK0778023T3 (ko)
ES (1) ES2188730T3 (ko)
HU (1) HUP9603370A3 (ko)
IL (1) IL119778A (ko)
MX (1) MX9606131A (ko)
NO (1) NO309966B1 (ko)
NZ (1) NZ299888A (ko)
PT (1) PT778023E (ko)
SI (1) SI0778023T1 (ko)
SK (1) SK154796A3 (ko)
TW (1) TW427904B (ko)
ZA (1) ZA9610245B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079177A1 (en) * 2000-04-17 2001-10-25 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
WO2004091633A1 (en) * 2003-04-09 2004-10-28 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
PT1611144E (pt) 2003-04-09 2010-11-12 Wyeth Llc Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda)
US20070155771A1 (en) * 2003-04-11 2007-07-05 David Rubinsztein Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
JP2008524232A (ja) 2004-12-20 2008-07-10 ワイス ラパマイシン誘導体及び神経障害の治療におけるその使用
US7276498B2 (en) * 2004-12-20 2007-10-02 Wyeth Rapamycin analogues and uses thereof in the treatment of neurological disorders
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
CN102612564B (zh) * 2009-04-10 2015-08-26 齐海燕 新的抗衰老试剂及其鉴别方法
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2456437A4 (en) * 2009-07-24 2013-01-09 Inst Nat Rech Scient COMBINATION THERAPY FOR TAUOPATHIES
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) * 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
SI3003268T1 (sl) 2013-06-05 2019-01-31 Pharnext Stabilne oralne raztopine za kombinirane API
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
KR20200088856A (ko) * 2017-11-15 2020-07-23 벤더르빌트 유니버시티 리소좀 기능의 개선 및 퇴행성 신경 질환의 치료를 위한 방법 및 조성물
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532862A1 (en) * 1991-07-25 1993-03-24 University Of Louisville Research Foundation, Inc. Use of rapamycin for the preparation of a medicament for the treatment of ocular inflammation
JPH05170668A (ja) * 1991-06-05 1993-07-09 Schering Ag パーキンソン症候群を治療するための薬剤学的製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05170668A (ja) * 1991-06-05 1993-07-09 Schering Ag パーキンソン症候群を治療するための薬剤学的製剤
EP0532862A1 (en) * 1991-07-25 1993-03-24 University Of Louisville Research Foundation, Inc. Use of rapamycin for the preparation of a medicament for the treatment of ocular inflammation
JPH05194212A (ja) * 1991-07-25 1993-08-03 Univ Louisville Res Found Inc 眼炎症処置方法

Also Published As

Publication number Publication date
HU9603370D0 (en) 1997-01-28
HUP9603370A2 (en) 1997-05-28
AU7417896A (en) 1997-06-12
TW427904B (en) 2001-04-01
MX9606131A (es) 1997-08-30
DE69626610D1 (de) 2003-04-17
ATE234095T1 (de) 2003-03-15
CN1159915A (zh) 1997-09-24
SI0778023T1 (en) 2003-08-31
HUP9603370A3 (en) 1998-12-28
DK0778023T3 (da) 2003-06-30
BR9605895A (pt) 1998-08-18
NO309966B1 (no) 2001-04-30
CN1112925C (zh) 2003-07-02
DE69626610T2 (de) 2003-10-02
CZ6498A3 (cs) 1998-06-17
SK154796A3 (en) 1997-09-10
IL119778A (en) 1999-07-14
NZ299888A (en) 2001-02-23
CZ354496A3 (cs) 1998-03-18
ZA9610245B (en) 1998-06-05
EP0778023A1 (en) 1997-06-11
PT778023E (pt) 2003-06-30
CA2192298A1 (en) 1997-06-08
ES2188730T3 (es) 2003-07-01
NO965238L (no) 1997-06-09
IL119778A0 (en) 1997-03-18
EP0778023B1 (en) 2003-03-12
NO965238D0 (no) 1996-12-06
AR008747A1 (es) 2000-02-23
JPH09183727A (ja) 1997-07-15
AU700653B2 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
KR970032856A (ko) 신경보호제
Shih et al. Anticonvulsants for Soman-induced seizure activity1
Rogawski Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2, 3-benzodiazepines
De Sarro et al. Comparative anticonvulsant activity of some 2, 3-benzodiazepine derivatives in rodents
KR940005633A (ko) 약제학적으로 유용한 항경련제 설파메이트의 이미데이트 유도체
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE205493T1 (de) N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden
BR0314390A (pt) Moduladores aromáticos dos receptores hepáticos x
Block et al. Global ischemic neuronal damage relates to behavioural deficits: a pharmacological approach
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
BR0016217A (pt) Composto, processo para prepará-lo, composição farmacêutica, e, uso do composto
AU2342397A (en) N-aminoalkyldibenzothiophenecarboxamides; dopamine receptor subtype specific ligands
PT838223E (pt) Inibidor do edema cerebral
Haug et al. The combination of donepezil and procyclidine protects against soman-induced seizures in rats
NZ507303A (en) Quinolin-4-yl derivatives II and their use in treating neurodegenerative disease
IT1283110B1 (it) Composti a scheletro colchicinico,loro uso come farmaci e composizioni che li contengono
Fuller et al. Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist
LV11320A (lv) 1-arilcikloalkilsulfida sulfoksida vai sulfona atvasinajumu pielietosana depresijas satraukuma Parkinsona slimibas arstesanai
CO4410322A1 (es) Nuevos compuestos de carboxamida, sus sales farmaceuticamente aceptables y composiciones farmaceuticas que los contienen
Myhrer et al. Anticonvulsant effects of damage to structures involved in seizure induction in rats exposed to soman
NO980531D0 (no) Medikament for hemming av avhengighets og toleranse utviklet som fölge av et narkotisk smertestillende middel
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
BR0015404A (pt) Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application